bluebird bio recommended ahead of trial updates at JPMorgan JPMorgan recommends owning shares of bluebird bio ahead of upcoming clinical trial updates. The firm notes initial data from the Phase 1/2 HGB-205 study evaluating LentiGlobin in beta-thalassemia patients will be presented on June 14 at the European Hematology Association. JPMorgan has an Overweight rating on the stock with a $44 price target.
bluebird bio price target raised to $119 from $112 at Piper Jaffray Piper Jaffray raised its price target for bluebird bio to $119 following the company's Q4 results and reiterates an Overweight rating on the name. Piper sees 2015 as a "big year" for bluebird with preliminary sickle cell data.